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* EVIDENCE-BASED ANSWER 
Healthy, unimmunized children who have not had varicella infection should be vaccinated 
(strength of recommendation: A, based on randomized controlled trials). Use of the vaccine in 
immunocompromised children is still being studied and has not been approved by the Food and 
Drug Administration (FDA). 
* EVIDENCE SUMMARY 
Before the introduction of the varicella vaccine, almost 4 million cases of chickenpox occurred 
each year in the United States, resulting in 11,000 hospitalizations and 100 deaths. (1) Varicella 
is the leading cause of vaccine-preventable death in children. (2) 
In a search of the literature from 1966 to 2000, a systematic review identified 24 randomized 
controlled trials and 18 cohort studies of varicella vaccination. (3) In children aged 10 months to 
14 years, 1 randomized controlled trial found protective efficacy of 100% over 9 months and 
98% over 7 years. (4) A second trial showed efficacy of 72% over 29 months. (5) Cohort studies 
of children report that the vaccine is 84% to 86% effective in preventing varicella and 100% 
effective in preventing moderate to severe infections. (3) 
Cumulative results of all studies show the number needed to vaccinate to prevent 1 case of 
varicella ranges from 5.5 to 11.8, and the number needed to prevent 1 complicated case ranges 
from 550 to 1180. 
No direct evidence supports or refutes a reduction in varicella mortality or rates of 
hospitalization due to vaccination. Randomized controlled trials show no increase in rates of 
fever or rash among those receiving vaccine; however, cohort studies report fever (0%-36%), 
local injection site reactions (7%-30%), and rash (5%). (3) No clinical trials have shown 
transmission of vaccine-related varicella zoster virus in immuno-competent patients, and only 3 
proven cases of transmission of vaccine virus to susceptible contacts have been documented. (6) 
Some evidence suggests the incidence of herpes zoster is reduced in immunocompromised 
vaccine recipients, but long-term observation is needed to assess the effect on healthy recipients. 
(7) 
One concern about the vaccine is that waning immunity over time could result in increased 
incidence of varicella infection during adulthood. While existing studies document persistence of 
antibodies for up to 20 years following immunization, (3) long-term effectiveness should 
continue to be monitored. 
The FDA has not approved this live-virus vaccine for use in pregnant women and 
immunocompromised persons, including transplant recipients and persons receiving 
corticosteroid therapy. However, the vaccine has been very well-studied in children with 
leukemia. A review of these studies found that optimal seroconversion requires 2 sequential 
vaccine doses (86% efficacy). A rash of varying severity was the predominant adverse event in 
20% to 50% of vacinees. (7) Study of vaccine use in other immunocompromised children has 
been limited. Early results from a trial in HIV-infected children who were not severely 
immunocompromised suggests similar tolerance and efficacy compared with children without 
HIV. (8) 
A systemic review of cost-effectiveness of varicella vaccine is based predominantly on 
mathematical models. (9) These models show societal savings due to decrease in unproductive 
days for parents, but fail to demonstrate actual healthcare savings. 
* RECOMMENDATIONS FROM OTHERS 
The American Academy of Pediatrics (AAP), Advisory Committee on Immunization Practices 
(ACIP), and American Academy of Family Medicine all recommend vaccinating unimmunized 
children aged 12 months and older who have not had varicella infection, and not vaccinating 
children with cellular immunodeficiencies. (2,10,11) The AAP suggests the vaccine could be 
considered for children with acute lymphocytic leukemia and for HIV-infected children with 
mild or no signs or symptoms. The ACIP guidelines are similar, with the addition that children 
with impaired humoral immunity may now be vaccinated. 
Marcus Plescia, MD, MPH, Laura Leach, MLIS, Carolinas Healthcare System, Charlotte, NC 
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* CLINICAL COMMENTARY 
Encourage varicella vaccination, except for the immunocompromised 
For many parents, vaccination decisions are made based on school district requirements. 
Varicella zoster vaccine is an exception to that rule. Parents can choose to immunize their child 
at 12 months or wait and let nature take its course--hopefully before the child starts kindergarten. 
The major concern with the vaccine has been its long-term efficacy. Although no one knows for 
sure how long immunity is sustained, studies show that detectable antibodies are present for up 
to 20 years. 
As a parent and physician, my decision to vaccinate my daughter was made after I witnessed an 
8-year-old boy in the emergency room with respiratory distress secondary to complications from 
chickenpox. This experience reinforced for me that chickenpox is a life-threatening disease. The 
effects of chickenpox include scarring as well as time away from work for parents. I therefore 
encourage varicella vaccination for my patients, with the only exception being those who are 
immunocompromised, for whom we have no data. 
To the question of whether we should we vaccinate children to prevent chickenpox, I give a 
resounding "yes." 
Kristen Rundell, MD, University of Colorado Health Sciences Center Denver 
 
